A Company Built on Science
Mitovation is developing novel infrared light (IRL) technology for the treatment of ischemic brain injuries. With funding and support from the National Institutes of Health and U.S. Department of Defense, Mitovation’s founders and executive team are translating this groundbreaking technology from bench to bedside for the treatment of cardiac arrest, traumatic brain injury (TBI), stroke, and neonatal hypoxia.
Grants Awarded
Grant Funds
Patents
Papers Published
Our Story
Learn more about the company, its history, and the revolutionary technology we are building.
Our StoryLeadership Team
Our leaders bring a variety of perspectives and expertise in our mission to bring novel technology to the treatment of reperfusion brain injuries.
Leadership TeamAdvisory Board
Mitovation is honored to have nationally recognized medical leaders serve on its advisory board.
Advisory BoardLeadership Team
Bruce Barrett
Chairman & Chief Executive OfficerMr. Barrett has almost 30 years of experience bringing new near-infrared light-based medical innovations to market. His career began in sales at Edwards Lifesciences. At Abbott Laboratories, he ran sales and marketing for the critical care business and was responsible for the Canadian Hospital Product’s Division. He was CEO of Somanetics Corporation (Troy, MI), a public company, from early development until its sale to Covidien. He was also CEO of Ornim Medical (Israel), a private venture capital backed medical device start-up.
Maik Hüttemann
Founder & Co-Chief Science OfficerDr. Hüttemann is Professor and Division Director for Research at the Center for Molecular Medicine & Genetics at Wayne State University School of Medicine. His research focus is mitochondrial bioenergetics- his work led to the discovery that discrete wavelengths of infrared light can positively modulate mitochondria of cells during the critical reperfusion period after an ischemic injury.
Thomas Sanderson
Founder & Co-Chief Science OfficerDr. Sanderson is Associate Professor in the Department of Emergency Medicine and Molecular and Integrative Physiology at the University of Michigan. He serves as a grant reviewer for the NIH, DoD, and American Heart Association (AHA), and has received numerous research excellence awards from the AHA. His research focus is in cardiac arrest and resuscitation, translation of therapeutics, and mitochondrial dysfunction.
Tom Waddell
Chief Operating OfficerMr. Waddell has over 30+ years of medical device project leadership. He currently serves as CEO of Waddell Group, a medical device project management consultancy, and has led over 40+ medical device projects from concept through launch in multiple medical markets.